Evidence map›Paper›PMID 38455390›Full record

ArticleEpigenetics communications2023

Comprehensive Evaluation of The Infinium Human MethylationEPIC v2 BeadChip.

Diljeet Kaur, Sol Moe Lee, David Goldberg, Nathan J Spix, Toshinori Hinoue, Hong-Tao Li, Varun B Dwaraka, Ryan Smith, Hui Shen, Gangning Liang and 3 more

Abstract read
In one paragraph

Article in Epigenetics communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. DNA Methylation-Based Risk Stratification and Classification of Pediatric Thyroid Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Diljeet KaurCenter for Computational and Genomic Medicine, The Children's Hospital of Philadelphia, PA, 19104, USA.
Sol Moe LeeCenter for Computational and Genomic Medicine, The Children's Hospital of Philadelphia, PA, 19104, USA.
David GoldbergCenter for Computational and Genomic Medicine, The Children's Hospital of Philadelphia, PA, 19104, USA.
Nathan J SpixDepartment of Epigenetics, Van Andel Institute, Grand Rapids, MI 49503, USA.
Toshinori HinoueDepartment of Epigenetics, Van Andel Institute, Grand Rapids, MI 49503, USA.
Hong-Tao LiDepartment of Urology, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA.
Varun B DwarakaTruDiagnostic Inc, Lexington, KY 40503, USA.
Ryan SmithTruDiagnostic Inc, Lexington, KY 40503, USA.
Hui ShenDepartment of Epigenetics, Van Andel Institute, Grand Rapids, MI 49503, USA.
Gangning LiangDepartment of Urology, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA.
Nicole RenkeIllumina, Inc., Product Management Department, San Diego, CA 92122, USA.
Peter W LairdDepartment of Epigenetics, Van Andel Institute, Grand Rapids, MI 49503, USA.
Wanding ZhouCenter for Computational and Genomic Medicine, The Children's Hospital of Philadelphia, PA, 19104, USA.

Funding

Decoding Single-cell DNA Methylomes for Epigenetic Cell IdentityR35GM146978 · NIGMS · CHILDREN'S HOSP OF PHILADELPHIA · PI Wanding Zhou · 2022 to 2026
$2.2M
NIGMS NIH HHS R35 GM146978
6 · The paper itself

Abstract

Infinium Methylation BeadChips are widely used to profile DNA cytosine modifications in large cohort studies for reasons of cost-effectiveness, accurate quantification, and user-friendly data analysis in characterizing these canonical epigenetic marks. In this work, we conducted a comprehensive evaluation of the updated Infinium MethylationEPIC v2 BeadChip (EPICv2). Our evaluation revealed that EPICv2 offers significant improvements over its predecessors, including expanded enhancer coverage, applicability to diverse ancestry groups, support for low-input DNA down to one nanogram, coverage of existing epigenetic clocks, cell type deconvolution panels, and human trait associations, while maintaining accuracy and reproducibility. Using EPICv2, we were able to identify epigenome and sequence signatures in cell line models of

Identifiers

PMID38455390
PMCPMC10919401

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.